Efficacy of Human Papillomavirus Vaccines in the Prevention of Male Genital Diseases: A Systematic Review Publisher Pubmed

Summary: Can HPV vaccines protect men? RCTs find quadrivalent vaccine cuts genital warts & HPV infection. #HPVVaccine #MensHealth

Kardoust Parizi M^{1, 3} ; Singla N⁵ ; Matsukawa A^{1, 8} ; Tsuboi I^{1, 9} ; Mancon S^{1, 10} ; Miszczyk M^{1, 11} ; Chlosta P¹² ; Shariat SF^{1, 2, 4, 6, 7, 13, 14}
Source: BJU International Published:2025

Abstract

Objectives: To evaluate the results of randomised controlled trials (RCTs) regarding the efficacy of human papillomavirus (HPV) vaccination in preventing male genital-related diseases. Methods: A systematic search of English language literature using PubMed, Scopus, and Cochrane Library was performed in April 2024 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol. Results: Evidence from four RCTs (including 7008 male participants) support the efficacy of the quadrivalent HPV vaccine in preventing genital warts and persistent HPV infection in HPV-naive men. The low incidence of male genital malignancies in the control groups of the reported studies lead to underpowered evidence. However, vaccination leads to durable protection with a long-term follow-up of 10 years showing efficacy of 91.8% to prevent HPV 6-, 11-, 16-, or 18-related external genital lesions (EGLs) in HPV-naive subjects. Additionally, the quadrivalent vaccine seems to effectively reduce the detection of DNA from all four HPV types. Conclusion: In summary, early quadrivalent HPV vaccination demonstrates efficacy in preventing HPV infection and EGLs in males. Well controlled prospective studies are needed to confirm the long-term efficacy, specifically in cancer prevention, in all men and specific subject subgroups, and to identify the targeted population who is most likely to benefit from early vaccination. © 2025 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International.